US LNG exports surge but will buyers in China turn up?
Catherine Cusack, a director at Sabra Health Care REIT (NYSE:WELL), Inc. (NASDAQ:SBRA), a $3.88 billion healthcare REIT known for its 7.56% dividend yield, recently made two notable purchases of the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, Cusack acquired a total of 2,500 shares over two separate transactions.
On February 21, Cusack purchased 1,000 shares at a price of $16.435 per share. This was followed by another acquisition of 1,500 shares on February 24 at a price of $15.92 per share. The total value of these transactions amounts to $40,315. InvestingPro data shows the company maintains a GOOD financial health score, with analysts generally maintaining a positive outlook on the stock.
Following these purchases, Cusack holds a total of 60,583 shares. This figure includes 3,268 unvested stock units and 42,815 stock units that have vested, although payment has been deferred. Each stock unit represents the right to receive one share of Sabra Health Care REIT’s common stock. The company has maintained consistent dividend payments for 15 consecutive years, demonstrating strong shareholder commitment. For more detailed analysis and insights, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Sabra Healthcare REIT Inc . has been the focus of several significant analyst assessments. JMP Securities upgraded Sabra Healthcare from Market Perform to Market Outperform, setting a new price target of $20.00, based on expectations of strong growth in senior housing assets and improved rent coverage ratios. This upgrade reflects optimism about the company’s value creation potential in the coming years. Meanwhile, Truist Securities maintained its Buy rating for Sabra Healthcare with a price target of $18.00, citing stable earnings growth potential and a premium valuation relative to peers.
In contrast, Mizuho (NYSE:MFG) downgraded Sabra Healthcare from Outperform to Neutral, adjusting the price target to $20.00 due to concerns over potential regulatory changes and increased competition in senior housing deals. The downgrade reflects a more cautious outlook on the sector’s future dynamics. Despite varying analyst opinions, Sabra Healthcare’s stock is noted to be trading at a premium compared to its historical averages. These recent developments indicate a mixed outlook for Sabra Healthcare, with differing views on its near-term growth prospects and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.